{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:17:26Z","timestamp":1769105846013,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11897-018-0413-9","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T17:28:39Z","timestamp":1542043719000},"page":"390-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hyperkalaemia in Heart Failure\u2014Pathophysiology, Implications and Therapeutic Perspectives"],"prefix":"10.1007","volume":"15","author":[{"given":"Redi","family":"Llubani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davor","family":"Vukadinovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Zewinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"413_CR1","unstructured":"Cardiovascular diseases-fact sheet. World Health Organization. \n                      http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/\n                      \n                    . 21 Oct 2016."},{"key":"413_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","volume":"113","author":"VL Roger","year":"2013","unstructured":"Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646\u201359.","journal-title":"Circ Res"},{"key":"413_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891\u2013975.","journal-title":"Eur J Heart Fail"},{"key":"413_CR4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.ekir.2017.07.001","volume":"2","author":"PH Pun","year":"2017","unstructured":"Pun PH, Goldstein BA, Gallis JA, Middleton JP, Svetkey LP. Serum potassium levels and risk of sudden cardiac death among patients with chronic kidney disease and significant coronary artery disease. Kidney International Rep. 2017;2:1122\u201331.","journal-title":"Kidney International Rep"},{"key":"413_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.510","volume":"18","author":"M Komajda","year":"2016","unstructured":"Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, et al. Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18:514\u201322.","journal-title":"Eur J Heart Fail"},{"key":"413_CR6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Anker SD, Dahlstrom U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173\u201384.","journal-title":"Eur J Heart Fail"},{"key":"413_CR7","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21:S212\u201320.","journal-title":"Am J Manag Care"},{"key":"413_CR8","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur J Heart Fail. 2017;38:1883\u201390.","journal-title":"Eur J Heart Fail"},{"key":"413_CR9","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehv268","volume":"36","author":"M Edner","year":"2015","unstructured":"Edner M, Benson L, Dahlstrom U, Lund LH. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur J Heart Fail. 2015;36:2318\u201326.","journal-title":"Eur J Heart Fail"},{"key":"413_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","volume":"7","author":"O Vardeny","year":"2014","unstructured":"Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalaemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7:573\u20139.","journal-title":"Circ Heart Fail"},{"key":"413_CR11","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","volume":"118","author":"B Pitt","year":"2008","unstructured":"Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation. 2008;118:1643\u201350.","journal-title":"Circulation"},{"key":"413_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen D, et al. Incidence, determinants, and prognostic significance of hyperkalaemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7:51\u20138.","journal-title":"Circ Heart Fail"},{"key":"413_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","volume":"46","author":"AJ Collins","year":"2017","unstructured":"\u2022\u2022 Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes. Am J Nephrol. 2017;46:213\u201321 This real-world study demonstrates that serum potassium levels below or above the normal range are associated with a higher risk of death which is consistently higher in patients with (i.e. HF, CKD and\/or DM).","journal-title":"Am J Nephrol"},{"key":"413_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"BF Palmer","year":"2004","unstructured":"Palmer BF. Managing hyperkalaemia caused by inhibitors of the renin-angiotensin-aldosterone system. NEJM. 2004;351:585\u201392.","journal-title":"NEJM"},{"issue":"15","key":"413_CR15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939\u201345.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"413_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00392-018-1260-0","volume":"107","author":"N Marx","year":"2018","unstructured":"\u2022\u2022 Marx N, Noels H, Jankowski J, Floege J, Fliser D, B\u00f6hm M. Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clin Res Cardiol. 2018;107(Suppl 2):120\u20136. \n                      https:\/\/doi.org\/10.1007\/s00392-018-1260-0\n                      \n                     This review article summarizes the current understanding of the pathophysiology of CVD in patients with CKD, defines the gaps in knowledge and describes the structure of the German Transregional Research Consortium SFB TRR219 which addresses \u201cMechanisms of Cardiovascular Complications in Chronic Kidney Disease\u201d.","journal-title":"Clin Res Cardiol"},{"key":"413_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. NEJM. 2000;342:145\u201353.","journal-title":"NEJM"},{"key":"413_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. NEJM. 2001;345:861\u20139.","journal-title":"NEJM"},{"key":"413_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEJM. 1999;341:709\u201317.","journal-title":"NEJM"},{"key":"413_CR20","doi-asserted-by":"crossref","unstructured":"Raquel L\u00f3pez-Vilella et al., Hyperkalaemia in heart failure patients: current challenges and future prospects. Dovepress 2016 Volume 2016:7 Pages 1\u20148.","DOI":"10.2147\/RRCC.S75680"},{"issue":"14","key":"413_CR21","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jacc.2016.06.060","volume":"68","author":"Chaudhry M.S. Sarwar","year":"2016","unstructured":"Sarwar Chaudhry MS, Papadimitriou Lampros, Pitt Bertram, Pi\u00f1a Ileana, Zannad Faiez, Anker Stefan D, Gheorghiade Mihai, Butler Javed. \/ Hyperkalemia in Heart Failure. In: Journal of the American College of Cardiology. 2016;68(14):1575\u20131589","journal-title":"Journal of the American College of Cardiology"},{"issue":"oct23 1","key":"413_CR22","doi-asserted-by":"publisher","first-page":"b4114","DOI":"10.1136\/bmj.b4114","volume":"339","author":"M. J Nyirenda","year":"2009","unstructured":"Nyirenda MJ, Tang J, Padfield PL, Seckl JR. Hyperkalaemia. BMJ 2009;339:b4114.","journal-title":"BMJ"},{"key":"413_CR23","unstructured":"Jeffrey D. Dunn, et al. The burden of hyperkalaemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015;21:S307\u201315."},{"key":"413_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00467-010-1699-3","volume":"26","author":"A Lehnhardt","year":"2011","unstructured":"Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalaemia. Pediatr Nephrol. 2011;26:377\u201384.","journal-title":"Pediatr Nephrol"},{"issue":"Issue 38","key":"413_CR25","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","volume":"38","author":"M Aldahl","year":"2017","unstructured":"\u2022 Aldahl M, Jensen AC, Davidsen L, et al. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J. 2017;38(Issue 38):2890\u20136 This investigation shows that levels within the lower and upper levels of the normal serum potassium range (3.5\u20134.1\u00a0mmol\/L and 4.8\u20135.0\u00a0mmol\/L, respectively) were associated with a significant increased short-term risk of death and increased mortality in chronic heart failure patients.","journal-title":"Eur Heart J"},{"key":"413_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjcard.2016.09.038","volume":"119","author":"J Tromp","year":"2017","unstructured":"Tromp J, Ter Maaten JM, Damman K, et al. Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials). Am J Cardiol. 2017;119:290\u20136.","journal-title":"Am J Cardiol"},{"key":"413_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/eurjhf\/hfp108","volume":"11","author":"K Damman","year":"2009","unstructured":"Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail. 2009;11:847\u201354.","journal-title":"Eur J Heart Fail"},{"key":"413_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"J McMurray","year":"2014","unstructured":"McMurray J, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. NEJM. 2014;371:993\u20131004.","journal-title":"NEJM"},{"key":"413_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalaemia after publication of the Randomized Aldactone Evaluation Study. NEJM. 2004;351:543\u201351.","journal-title":"NEJM"},{"key":"413_CR30","doi-asserted-by":"crossref","unstructured":"Dev S, Lacy ME, Masoudi FA, Wu WC. Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure. J Am Heart Assoc. 2015;4(12):e002268.","DOI":"10.1161\/JAHA.115.002268"},{"key":"413_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","volume":"188","author":"D Vukadinovic","year":"2017","unstructured":"\u2022 Vukadinovic D, Lavall D, Vukadinovic AN, Pitt B, Wagenpfeil S, Bohm M. True rate of mineralocorticoid receptor antagonists-related hyperkalaemia in placebo-controlled trials: a meta-analysis. Am Heart J. 2017;188:99\u2013108 This meta-analysis shows that in clinical trials, non-MRA-related rises in potassium levels might be underestimated and should be rigorously explored before cessation of the evidence-based therapy with MRAs.","journal-title":"Am Heart J"},{"key":"413_CR32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","volume":"24","author":"LC Liu","year":"2015","unstructured":"Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA. Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs. 2015;24:1123\u201335.","journal-title":"Expert Opin Investig Drugs"},{"key":"413_CR33","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur J Heart Fail. 2013;34:2453\u201363.","journal-title":"Eur J Heart Fail"},{"key":"413_CR34","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur J Heart Fail. 2016;37:2105\u201314.","journal-title":"Eur J Heart Fail"},{"key":"413_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/ejhf.226","volume":"17","author":"A Michel","year":"2015","unstructured":"Michel A, Mart\u00edn-P\u00e9rez M, Ruig\u00f3mez A, Garc\u00eda Rodr\u00edguez LA. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail. 2015;17:205\u201313.","journal-title":"Eur J Heart Fail"},{"key":"413_CR36","unstructured":"Health Quality Improvement Partnership. National Heart Failure Audit. April 2014\u2013March 2015. Available at: \n                      http:\/\/www.hqip.org.uk\/resources\/national-heart-failure-audit-2014-2015\/\n                      \n                    . Accessed: January 2018."},{"issue":"4","key":"413_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s11897-017-0341-0","volume":"14","author":"EM DeFilippis","year":"2017","unstructured":"DeFilippis EM, Desai AS. Treatment of hyperkalaemia in heart failure. Curr Heart Fail Rep. 2017;14(4):266\u201374.","journal-title":"Curr Heart Fail Rep"},{"key":"413_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","volume":"2","author":"AS Desai","year":"2017","unstructured":"Desai AS, Vardeny O, Claggett B, McMurray JJV, Packer M, Swedberg K, et al. Reduced risk of hyperkalaemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology. 2017;2:79\u201385.","journal-title":"JAMA Cardiology"},{"key":"413_CR39","doi-asserted-by":"crossref","unstructured":"Burnett H, Earley A, Voors AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail. 2017;10(1):e003529.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529"},{"key":"413_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"413_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/CE.S129555","volume":"12","author":"V Mario","year":"2017","unstructured":"Mario V, Beccari, Meaney CJ. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalaemia: an evidence-based review. Core Evid. 2017;12:11\u201324.","journal-title":"Core Evid"},{"key":"413_CR42","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F, Pi\u00f1a IL, McCullough PA, Filippatos G, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17:1050\u20136.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"413_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, el-Shahawy MA, Roger SD, Block G, et al. Sodium zirconium cyclosilicate in hyperkalaemia. N Engl J Med. 2015;372(3):222\u201331.","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"413_CR44","first-page":"55","volume":"19","author":"B Pitt","year":"2017","unstructured":"Pitt B, Garza D, Zawadzki R, et al. Long-term effects of patiromer for hyperkalaemia treatment in patients with HFrEF and diabetic nephropathy on RAASi. Eur J Heart Fail. 2017;19(Suppl. 1):55.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"413_CR45","doi-asserted-by":"publisher","first-page":"e13052","DOI":"10.1111\/ijcp.13052","volume":"72","author":"Eirini Palaka","year":"2018","unstructured":"Palaka E, Leonard S, Buchanan-Hughes A, Bobrowska A, Langford B, Grandy S. Evidence in support of hyperkalaemia management strategies: a systematic literature review. Int J Clin Pract. 2018;72:e13052.","journal-title":"International Journal of Clinical Practice"},{"key":"413_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, et al. Effect of patiromer on serum potassium level in patients with hyperkalaemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314:151\u201361.","journal-title":"JAMA"},{"key":"413_CR47","unstructured":"European Medicines Agency. Patiromer: summary of product characteristics. Available at: \n                      http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/004180\/WC500232689.pdf\n                      \n                    . Accessed: January 2018."},{"key":"413_CR48","unstructured":"European Medicines Agency. Veltassa EPAR summary for the public. Available at: \n                      http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/004180\/WC500232692.pdf\n                      \n                    . Accessed: January 2018."},{"key":"413_CR49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.phrs.2016.07.032","volume":"118","author":"B Pitt","year":"2017","unstructured":"Pitt B, Rossignol P. Potassium lowering agents: recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalaemia. Pharmacol Res. 2017;118:2\u20134.","journal-title":"Pharmacol Res"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-018-0413-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-018-0413-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-018-0413-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T19:17:07Z","timestamp":1573499827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-018-0413-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1007\/s11897-018-0413-9","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"12 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Redi Llubani, Davor Vukadinovi\u0107, Christian Werner, Nikolaus Marx and Stephen Zewinger declare no conflicts of interest.Michael B\u00f6hm reports personal fees from Amgen, personal fees from Bayer, personal fees from Servier, personal fees from Medtronic, personal fees from Boehringer Ingelheim, personal fees from Vifor and personal fees from Bristol Myers Squibb, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}